<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11429">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575029</url>
  </required_header>
  <id_info>
    <org_study_id>26835</org_study_id>
    <nct_id>NCT00575029</nct_id>
  </id_info>
  <brief_title>Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate</brief_title>
  <official_title>Evaluation of the Time Course of Adrenal Suppression and Adrenal Recovery After Ingestion of Megestrol Acetate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Megestrol Acetate (MA) is a progesterone-like hormone that has been utilized as a birth
      control agent, chemotherapeutic drug, and more recently, to induce appetite and weight gain
      in patients malnourished as a result of radiation therapy, chemotherapy, cystic fibrosis,
      AIDS, or dementia. The mechanism of MA-stimulated appetite and weight gain is unknown.

      Although only approved to combat weight loss associated with AIDS and cancer, MA is
      frequently prescribed for long periods of time to prevent or reverse weight loss in nursing
      home residents and in elderly patients with serious illnesses in the community. Little data
      is available to support this practice. Among its many properties, MA acts as a partial
      glucocorticoid agonist, and long term and short term use of MA may results in adrenal
      suppression. The rapidity of the onset of MA-induced adrenal suppression and the time course
      of resumption of normal adrenal function after discontinuation of MA is completely unknown.
      As a consequence, it is unclear whether MA can be given safely for short periods of time or
      whether glucocorticoid administration is necessary after abruptly stopping MA treatment. The
      increased use of MA in the frail elderly, where even partial adrenal insufficiency may pose
      a substantial risk of adrenal crisis after an illness, requires a clear understanding of
      these issues. To address these concerns, we will evaluate adrenal function before, during,
      and after MA administration in healthy volunteers between the ages of 60 and 85 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Number of Participants With Adrenal Insufficiency</measure>
    <time_frame>stimulated acth stimulated cortisol levels weekly for 8 weeks or until adrenal insufficiency is encountered</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adrenal insufficiency after treatment with megestrol acetate assessed by ACTH stimulated cortisol levels less than normal (21 ug/dl) measured weekly for 8 weeks or when adrenal insufficiency is clinically encountered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Required for Recovery From Adrenal Suppression to Normal Adrenal Function</measure>
    <time_frame>weekly for up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of weeks required for participants to recover from adrenal suppression as assessed by a normal ACTH stimulation test (cortisol level &gt;21 mcg/dl)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>megace treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will be given 600mg of MA for oral ingestion per day for duration of 8 weeks. They will be monitored every week clinically for the development of adrenal insufficiency by review of symptoms, physical exam, body weight, pulse, and blood pressure. Subjects also will undergo biochemical evaluation of adrenal status every two weeks by measurement of serum electrolytes, serum cortisol, serum adrenocorticotropic hormone(ACTH) levels, and the adrenal response to a low dose ACTH (1Âµgm) stimulation test(see methods).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>megestrol acetate</intervention_name>
    <description>600 mg by mouth daily</description>
    <arm_group_label>megace treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly males and females

          -  Age 65-80 years

          -  With stable (no history of urgent/ emergent care visits with health care provider/s
             in the preceding 2 months), medical conditions

        Exclusion Criteria:

        Subjects will be excluded if they have a history of (H/O):

          -  Dementia

          -  Adrenal disease

          -  Thromboembolism

          -  Diabetes mellitus

          -  Liver disease

          -  Electrolyte abnormalities; or

          -  Vaginal bleeding

          -  Hypertriglyceridemia

          -  CAD with CHF

          -  Unstable depression

          -  Schizophrenia; and

          -  Morbidly obese subjects.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>donald l bodenner</last_name>
    <role>Principal Investigator</role>
    <affiliation>associate professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas For Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 27, 2011</lastchanged_date>
  <firstreceived_date>December 13, 2007</firstreceived_date>
  <firstreceived_results_date>March 31, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Donald Bodenner MD</name_title>
    <organization>university of arkansas for medical sciences</organization>
  </responsible_party>
  <keyword>megestrol acetate</keyword>
  <keyword>adrenal insufficiency</keyword>
  <keyword>adrenal suppression</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment 4/04 to 7/04.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Megestrol Acetate</title>
          <description>Study subjects will be given 600mg of MA (megestrol acetate) for oral ingestion per day for duration of 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Megestrol Acetate</title>
          <description>Study subjects will be given 600mg of MA (megestrol acetate) for oral ingestion per day for duration of 8 weeks.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="68" spread="5.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adrenal Insufficiency</title>
        <description>Number of participants with adrenal insufficiency after treatment with megestrol acetate assessed by ACTH stimulated cortisol levels less than normal (21 ug/dl) measured weekly for 8 weeks or when adrenal insufficiency is clinically encountered</description>
        <time_frame>stimulated acth stimulated cortisol levels weekly for 8 weeks or until adrenal insufficiency is encountered</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Megestrol Acetate</title>
            <description>Study subjects will be given 600mg of MA (megestrol acetate) for oral ingestion per day for duration of 8 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adrenal Insufficiency</title>
            <description>Number of participants with adrenal insufficiency after treatment with megestrol acetate assessed by ACTH stimulated cortisol levels less than normal (21 ug/dl) measured weekly for 8 weeks or when adrenal insufficiency is clinically encountered</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Required for Recovery From Adrenal Suppression to Normal Adrenal Function</title>
        <description>the number of weeks required for participants to recover from adrenal suppression as assessed by a normal ACTH stimulation test (cortisol level &gt;21 mcg/dl)</description>
        <time_frame>weekly for up to 6 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Megestrol Acetate</title>
            <description>Study subjects will be given 600mg of MA (megestrol acetate) for oral ingestion per day for duration of 8 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time Required for Recovery From Adrenal Suppression to Normal Adrenal Function</title>
            <description>the number of weeks required for participants to recover from adrenal suppression as assessed by a normal ACTH stimulation test (cortisol level &gt;21 mcg/dl)</description>
            <units>weeks</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>participant 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>participant 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>participant 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>participant 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>participant 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>participant 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>participant 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Megestrol Acetate</title>
          <description>Study subjects will be given 600mg of MA (megestrol acetate) for oral ingestion per day for duration of 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>funding became an issue limiting the number of patients enrolled</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Donald Bodenner</name_or_title>
      <organization>University of Arkansas</organization>
      <phone>501-526-5710</phone>
      <email>bodennerdonald@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
